“I have a deep belief that medtech and healthtech are going to carry us forward to markedly improve delivery and quality of healthcare.”  - Jonathan P. Gertler, MD For years, biotech has been the dominant theme in life sciences development, offering a great deal in treatment advances and in terms of investing versatility and returns potential. But with promising system solutions serving broader swaths of patients, medtech is resurging. Medtech investment has grown dramatically over time, with scale and diversification capable of weathering economic storms and fueling expansion in the markets. Medtech is a significant driver of our healthcare economy, contributing to more meaningful patient care solutions and technology that continue to move care further from the hospital and more toward the home.  In this episode of The Life Science Report, Back Bay Life Science Advisors’ industry podcast, Dr. Jonathan Gertler speaks with Paul LaViolette Managing Partner & COO, SV Health Investors about the varying elements of medtech investments, including structured deals and strategies, the regulatory changes that are driving medtech forward and how more cost-effective care will be a turning point for granting access to more and more patients.  Topics in this podcast include: 
The role of investment in medtech and how to match capital to the asset or company
Why “incremental" is a four-letter word in the world of venture
How medtech is a systems solution provider, which differs from biotech as a disease modifier based on increasing patient segmentation 
How structured deals, traditionally the territory of biotech, have found their way deeply into medtech M&A and how the public markets are offering alternatives in a more robust way than recent history has shown
The regulatory changes for medtech in Europe and the profound impact this has on how investors and buyers make decisions
Subscribe to our industry podcast, The Life Science Report, and follow Back Bay Life Science Advisors on LinkedIn. Thank you for joining us.